Research ArticleHIV

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model

See allHide authors and affiliations

Science Translational Medicine  07 Aug 2019:
Vol. 11, Issue 504, eaav5685
DOI: 10.1126/scitranslmed.aav5685

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Driving a new HIV therapy forward

CAR T cells, which are now associated with cancer therapy, were previously investigated as a treatment for HIV almost 30 years ago. Now wielding new technology and biological knowledge, Anthony-Gonda et al. report a series of multispecific anti-HIV CARs. These CARs target different portions of the HIV envelope protein and were able to eliminate diverse strains of HIV in vitro, even those that are resistant to potent broadly neutralizing antibodies. The CAR T cells are resistant to HIV infection and were able to control HIV in a humanized mouse model. The persistent surveillance capabilities of CAR T cells suggest that this therapy may one day be able to eradicate HIV in an infected person.

View Full Text